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Abstract
Background: While the impact of conflicts-of-interest (COI) is of increasing concern in academic medicine, there is
little research on the reaction of practicing clinicians to the disclosure of such conflicts. We developed two
research vignettes presenting a fictional antidepressant medication study, one in which the principal investigator
had no COI and another in which there were multiple COI disclosed. We confirmed the face validity of the COI
vignette through consultation with experts. Hospital-based clinicians were randomly assigned to read one of these
two vignettes and then administered a credibility scale.
Findings: Perceived credibility ratings were much lower in the COI group, with a difference of 11.00 points
(31.42%) on the credibility scale total as calculated through the Mann-Whitney U test (95% CI = 6.99 - 15.00,
p < .001). Clinicians in the COI group were also less likely to recommend the antidepressant medication discussed
in the vignette (Odds Ratio = 0.163, 95% CI = .03 = 0.875).
Conclusions: In this study, increased disclosure of COI resulted in lower credibility ratings.
Background
The impact of financial conflicts-of-interest (COI) in
medicine is a topic of increasing concern [1]. Several
studies have found that financial COI play an important
role in the presentation and interpretation of research
[2,3], and that studies sponsored by industry are more
likely to result in the publication of positive findings
[4-6]. At present, most medical journals address the
issue by requiring that authors disclose their financial
COI in a competing interests statement [7].
A recent systematic review [8] finds only a few investi-
gations of the impact of financial COI disclosure on
clinicians, key consumers of medical research. In an oft-
cited study, readers of BMJ were sent an article on the
treatment of herpes zoster and randomly assigned to
receive either a version in which the authors declared
financial COI (as employees of a fictional pharmaceuti-
cal company) or declared no competing interests (as
clinicians at an ambulatory care center). Respondents
judged the version with disclosure of financial COI as
less valid and believable [9]. Similar findings from other
studies suggest that when financial COI are disclosed
revealing that the authors have a commercial interest in
the results, credibility ratings are lower [10,11]. In light
of evidence that financial COI do influence the content
of published research conclusions [2,4,12], these lower
credibility ratings in the presence of COI may be
justified.
Previous studies have tested the impact of financial
COI by presenting these COI in a relatively straightfor-
ward manner (e.g., testing the inclusion of a competing
interests statement accompanying a research article).
However, the information disclosed in competing inter-
ests statements is limited and may omit important infor-
mation. For instance, disclosure of competing interests
is currently limited to listing the corporations and agen-
cies that have paid or funded the investigator in the
recent past. The amounts of payments are typically not
listed. Whether a professor has received $1,000 or
$400,000 for consulting with a pharmaceutical company,
this financial COI will be listed in exactly the same way.
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the activities for which the investigator is paid. In the
recent past, there has been significant criticism of the
payment and utilization of “key opinion leaders” (KOLs)
[13-15]. KOLs are paid to consult with the marketing
departments of pharmaceutical companies, and to deli-
ver talks to physicians about the companies’ products.
Concerns have been raised about the scientific objectiv-
ity of KOLs [16].
Finally, an important issue in the management of COI
is that of ghostwriting. In this instance, a medical writer
(pharmaceutical company employee or subcontractor)
writes a manuscript in conjunction with the marketing
department of the company, and an academic researcher
is listed as author [17,18]. In many cases, the actual wri-
ter of the article is not listed as an author, which
amounts to an undisclosed COI, as the pharmaceutical
company’s involvement in the preparation of the manu-
script remains unacknowledged [19,20]. Ghostwritten
articles have been identified as sources of clandestine
commercial influence (e.g., [21]), and some research
suggests that such articles are impacting in the peer-
reviewed literature [22,23]. Since it is covert by defini-
tion, ghostwriting cannot be adequately managed
through the use of competing interests statements.
We sought to assess the impact of multiple types of
COI (financial COI, KOL status, and ghostwriting) on
the perceived credibility of biomedical research among
practicing clinicians, using a vignette design providing
information beyond that disclosed in a competing inter-
ests statement.
Methods
Two vignettes were created describing a fictional study
of a new antidepressant ("Serovux”)f o rp e d i a t r i cu s e .
Both research vignettes were identical in describing the
study sample, methods, and results, and in claiming that
Serovux was safe and effective for children, using lan-
guage derived from a well-known pediatric antidepres-
sant study [24]. Vignettes differed only in terms of their
financial COI and the method of authorship. In the
non-COI vignette (323 words long), the professor pre-
senting the research has no financial COI, is funded by
the National Institute of Mental Health (NIMH), does
not accept money from industry, and authors the article
in collaboration with colleagues.
In the COI vignette (411 words long), the professor
receives about $100,000 a year for ongoing KOL-type
consulting with the maker of the antidepressant, and the
manuscript is authored by a medical writer who is not
listed as a co-author. The COI content was based on
several known occurrences of ghostwriting, some of
which have emerged through legal discovery in medico-
legal cases [21,25,26]. The $100,000 COI amount was
derived from science media coverage of prominent
research psychiatrists receiving payments from industry
[27]. These vignettes are available as supplemental files
[Additional file 1 and additional file 2].
Five expert raters were asked to assess the COI vign-
ette for face validity. We selected raters who were aca-
demic researchers and who had published peer-reviewed
journal articles and/or scholarly books on ghostwriting.
Three of the five raters had served as medico-legal
experts in litigation involving ghostwritten journal arti-
cles. These expert raters opined that our vignettes had a
high level of face validity (see Table 1), and that the
vignette accurately reflected ghostwriting incidents
known to have occurred in real life.
Using items from two existing scales, we created a
short instrument (convenient to request participation
from busy clinicians in a hospital setting) comprising
three questions [28] asking respondents to rate how
truthful/accurate/credible they found the information
presented in the vignettes, and two questions [29] asking
respondents to rate how honest and sincere they found
the presenter of the information. These questions were
rated on a 7-point Likert-type scale. Clinicians were also
asked a yes/no question, “If a child you cared about was
severely depressed, would you recommend Serovux?”.
The questions and data are available as a supplemental
data file [Additional file 3].
Research participants were degreed personnel working
with hospital patients at a metropolitan hospital in the
Southwestern United States during Spring 2010, who
might be asked by patients for their opinion of a treat-
ment or therapeutic option. A medical social work
intern recruited clinicians by approaching them in the
hospital face-to-face, either individually or in groups
(e.g., staff meetings, Grand Rounds) and asking for their
participation in a research study. Participants were not
told that the purpose of the research was to examine
the impact of COI on research credibility; they were
asked only to assist an intern by participating in a
research project on “Perceptions of Biomedical
Research.” Vignettes were distributed so that the COI
condition was randomly assigned to participants. Data
collection took place between February 1, 2010 and
April 1, 2010. The research project was approved by
both hospital and University Institutional Review
Boards, and each participant provided informed consent.
We had two hypotheses based on the limited pub-
lished data:
Hypothesis 1: Clinicians randomized to read the COI
vignette will rate its information and presenter as less
credible than those in the non-COI group.
Hypothesis 2: Clinicians randomized to read the COI
vignette will be less likely to recommend the medication
than those in the non-COI group.
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3.04 [30]. Based on unpublished pilot data, we estimated
that we needed 23 participants in each group to detect a
5-point difference (14.29%) on the overall 35-point cred-
ibility scale between groups with 95% power. This calcu-
lation assumed a standard of deviation of 5 points in
each group, using a one-tailed independent t-test. Data
analysis was performed with PASW version 18.0 (SPSS
Inc., Chicago, IL, USA) and Minitab version 15.0 (Mini-
tab Inc., State College, Pennsylvania, USA).
Results
59 clinicians were approached and asked to complete
the instrument, of which 4 declined to participate and 5
agreed but did not return the instrument. This left 50
completed instruments for analysis, representing an
84.75% response rate.
Of the 50 participants, 17 (34%) were male and 20
(40%) were physicians (see Table 2). There were no
missing data for the credibility ratings. Using principal
components analysis (PCA), we found that only one
component could be extracted and that the 5-question
credibility scale was a unidimensional measure of cred-
ibility. The Cronbach’s alpha for the credibility scale was
0.946. The data were not normally distributed in the No
COI group (Shapiro-Wilk test = 0.896, p = .018).
To test Hypothesis 1, we utilized the nonparametric
Mann-Whitney U test to compare overall credibility
scores by vignette group (see Table 3). There was a
statistically significant difference between groups of
11.00 points (31.42%) on the credibility scale total
(95% CI = 6.99 - 15.00; p<. 0 0 1 ). This is a very large
effect size (Cohen’s d = 1.4), and Hypothesis 1 is
supported.
To test Hypothesis 2, the association between vign-
ette group and recommendation of Serovux was
assessed. Two respondents indicated that there was
not enough information to make a decision and did
not answer this question. Clinicians in the COI group
were less likely to recommend Serovux (Pearson c
2=
5.21, df =1 ,p = .022). The point estimates for this
reduced rate of recommendation were clinically signifi-
cant (OR = 0.163, 95% CI = .03 - 0.875; RR = 0.709,
95% CI = 0.515 - 0.976) and thus Hypothesis 2 is sup-
ported (see Figure 1).
We performed an influence analysis [31] by deleting
selected subgroups from the data one at time and
then re-running the analyses. Regardless of which
group was deleted (men, women, physicians, associ-
ates-level nurses, all other nurses), there remained a
statistically significant difference in credibility scores
between the COI and non-COI groups. Similarly, in
all subgroups the Serovux was less likely to be recom-
mended in the COI group. Of note, among the physi-
cians randomized to the COI group, none
recommended Serovux.
Table 1 Assessment of face validity by ghostwriting experts
Statement Level of Agreement
(n = 5)*
Percent of
Agreement
“Dr. Harvey is a Key Opinion Leader” 4.0 ±1.73† 80%
“The vignette accurately describes an incident of ghostwriting similar to those known to have occurred in
real life.”
4.6 ± 0.548 100%
“A psychiatrist who reads the antidepressant RCT literature is likely to come across studies that were
generated in a manner similar to that described in the vignette.” ‡
4.6 ± 0.548 100%
“The multiple conflicts-of-interest described in this vignette have been common among authors of RCTs
in the SSRI and SNRI literature.”
4.8 ± 0.447 100%
* Responses were on a 5-point Likert-type scale, with 1 = Strongly Disagree, 2 = Disagree, 3 = Neutral, 4 = Agree, 5 = Strongly Agree.
† Four of the five raters agreed, but there was one dissenting opinion of “1”.
‡ One rater wrote us asking for clarification, noting that subcontracted medical writers have been used in the antidepressant literature, while we described the
use of authors directly employed by the pharmaceutical company, a practice known to have occurred in publications on other medication classes such as Cox-2
inhibitors (26). We responded that the rater should decide whether a company employee is similar to a subcontractor when all the details are known. The rater
then submitted a rating of “4” (agree) for this question.
Table 2 Randomization of subjects by profession and vignette condition
Physician* Registered Nurse (Associates
Degree)†
Registered Nurse (Advanced
degree)‡
Social
Worker
Clinical
Dietician
NO COI Condition 10 3 8 2 1
COI + GW
Condition
10 8 5 2 1
* Includes 4 medical school students in clinical rotations.
† Groups are imbalanced; the difference is not statistically significant (Pearson c
2 = 2.82, df = 1,p=.093).
‡ Includes Bachelors, Masters, and Doctoral-level nurses.
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Hospital-based clinicians (n = 50) who read a fictional
vignette describing an antidepressant study found this
vignette much less credible when it was accompanied
with the disclosure of multiple COI (financial COI, KOL
status, and ghostwriting) than when no COI was pre-
sent. The effect size was very large (a 31.42% difference
in credibility scale total as measured by the Mann-
Whitney U test; Cohen’s d = 1.4). Clinicians were also
less likely to recommend the medication in the COI con-
dition (OR = 0.163). Influence analyses were performed
and the results were resistant to deletion of subgroups.
As Table 3 shows, respondents did not distinguish
between the honesty/sincerity of the presenter of the
information and the truthfulness/credibility of the study
data presented. While there was no content in either
vignette suggesting that the data was inaccurate, the
presence of multiple COI influenced respondents to per-
ceive the study data as less credible. Past research on
consumer trust suggests that trust increases when there
is clear accountability and regulation [32]. Since the
COI vignette involved a ghostwriting incident with no
safeguards and a violation of usual ethical publication
norms, this was likely one factor leading respondents to
rate the COI vignette as less credible. However, disclo-
sure of financial COI alone lowers perceived credibility
[9-11], and given our exploratory design it is not possi-
ble to isolate the differential impact of the multiple vari-
ables contained in the COI scenario. Some participants
may have been aware that selective reporting and sup-
pression of data have been a persistent problem in the
antidepressant literature [33,34], sometimes in conjunc-
tion with ghostwriting [21], and this may have impacted
their credibility ratings.
Interpreting the results of this study largely depends
on how realistic the COI vignette is perceived to be. If
the COI vignette is seen as a purely theoretical scenario,
then the study results may have little application to the
real world. However, this does not seem to be the case,
as our expert panel found the COI vignette to have
excellent face validity, with unanimous agreement that
the vignette described a situation similar to real-life.
The experts we consulted also reported that the multi-
ple COIs described in our vignette have been common
among authors of RCTs in the antidepressant literature,
and that psychiatrists reading the antidepressant RCT
literature will encounter articles generated in the man-
ner described in our COI vignette. Thus, while our use
of multiple COI is a potential drawback, it also repre-
sents the 1
st published data on how practicing clinicians
react to a realistic scenario where the authors simulta-
neously have multiple COI. Interestingly, one expert
characterized the COI vignette as an accurate portrayal
of how research on several other classes of medications
– such as mood-stabilizers [35], osteoporosis drugs, and
statins – has been produced. Our findings may thus
have application beyond the antidepressant literature.
Our finding that practicing clinicians discount scienti-
fic literature when multiple COIs are disclosed may be
useful to bioethicists, policymakers, journal editors, and
the pharmaceutical industry. For industry, the primary
funders of randomized controlled trials, our results
Table 3 Credibility ratings by conflict-of-interest condition*
Outcome Variable No COI (n = 24) COI Present (n = 26) Difference (95% CI)†
Truthful 5.12 ±1.67 3.15 ± 1.41
Accurate 4.83 ±1.46 2.96 ± 1.48
Credible 4.46 ±1.44 2.5 ± 1.63
Honest 5.0 ±1.67 2.81 ± 1.79
Sincere 4.75 ±1.60 3.23 ± 1.75
Overall Credibility (Scale Total) 24.17 ±6.91 14.65 ± 7.0 11.00 (6.99-15.00)‡
* Values are presented as means ± Standard Deviation. COI = Conflict-of-interest, CI = Confidence Interval.
†as calculated through nonparametric Mann-Whitney U test.
‡p < .001; Cohen’s d = 1.4, calculated by subtracting the COI present group mean from the No COI group and dividing by the pooled standard deviation.
Figure 1 Clinicians’ recommendation of Serovux cross-
tabulated by conflict-of-interest condition.
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interesting in light of new policy developments. New
legislation will shortly mandate increased disclosure of
industry payments to physicians, and once this informa-
tion is available on the internet, it will be a simple mat-
ter for medical journals to aggregate these data and
disclose the exact amounts of financial COI [36], exactly
as we did in our vignette. There may also be policy solu-
tions that would increase transparency in authorship
[19,37,38]. While these efforts may increase transpar-
ency, it will be in the interests of the pharmaceutical
industry to oppose their implementation; our results
suggest that increased transparency could lead to
reduced perceived credibility.
This small study, to our knowledge the first of its kind,
should be replicated. The results could be specific to the
hospital where the research was conducted, or there could
be unobserved confounds. We tested a set of COI (ghost-
writing, KOL status and financial COI) against no COI at
all, and so we could not separate out the impact of each
COI variable individually. A more complex vignette design
with more participants could do so, and, through using
ANOVA, such an analysis could determine whether there
are interaction effects between the various types of COI.
The COI information was presented before the clinical con-
tent of the vignette, instead of the end, as is the norm in
medical journals, and this might have impacted the credibil-
ity ratings [11,39]. Our vignette content on KOL status
could have been clearer. Despite these limitations, our
study provides information on how practicing clinicians
perceive research in which multiple COI are disclosed.
Additional material
Additional file 1: Vignette 1.pdf. Vignette in which the investigator has
no conflicts-of-interest.
Additional file 2: Vignette 2.pdf. Vignette in which the investigator has
multiple conflicts-of-interest.
Additional file 3: Data.xls. Complete dataset and codebook in Microsoft
Excel format.
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